Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Low Incidence of Deletions of ATM (ataxia-telangiectasia mutated) Gene in Patients (pts) with Multiple Myeloma (MM) as Detected by FISH.

Asher Alban Chanan-Khan, MD, Kena Miller, NP, Philip McCarthy, MD, Joanna M. Panasiewicz, AnneMarie W. Block, Ph.D.

Blood (2004) 104 (11): 4886.

https://doi.org/10.1182/blood.V104.11.4886.4886

Published: 2004

Journal Articles

AMD3100 Combined with Standard Doses of G-Csf Leads to Rapid, Consistent Mobilization of Hematopoietic Progenitor Cells in Patients with Non-Hodgkin’s Lymphoma (NHL) and Multiple Myeloma.

Patrick Stiff, MD, Ivana Micallef, MD, Philip McCarthy, MD, Margarida Magalhaes-Silverman, MD, Neal Flomenberg, MD, Daniel Weisdorf, MD, Guido Tricot, MD, Mary Territo, MD, Rafat Abonour, MD, Karin Badel, Gary Calandra, MD/PhD

Blood (2004) 104 (11): 2847.

https://doi.org/10.1182/blood.V104.11.2847.2847

Published: 2004

Journal Articles

VAD-t (Vincristine, Adriamycin, Dexamethasone and Low-Dose Thalidomide) Is an Effective Initial Therapy with High Response Rates for Patients with Treatment Naïve Multiple Myeloma (MM).

Asher Alban Chanan-Khan, MD, Kena C. Miller, NP, Philip McCarthy, MD, Alexandra Koryzna, RN, Peter Kouides, MD, Kathleen Donohue, Alice Mohr, NP, Zale P. Bernstein, MD, Arif Alam, MD, Myron S. Czuczman, MD

Blood (2004) 104 (11): 3463.

https://doi.org/10.1182/blood.V104.11.3463.3463

Published: 2004

Journal Articles

Thalidomide (T) in Combination with Fludarabine (F) as Initial Therapy for Patients (pts) with Treatment Naïve Chronic Lymphocytic Leukemia (CLL): Results of a Phase I Trial.

Asher Alban Chanan-Khan, MD, Kena Miller, NP, Alexandra Koryzna, RN, Kenichi Takeshita, MD, Philip McCarthy, MD, Alice Mohr, NP, Kathleen Donohue, Zale P. Bernstein, MD, Arif Alam, MD, Myron S. Czuczman, MD

Blood (2004) 104 (11): 3476.

https://doi.org/10.1182/blood.V104.11.3476.3476

Published: 2004

Journal Articles

Phase I/II Study of Rituxan (R) in Combination with Doxil (D) in Patients (pts) with Relapsing or Refractory B-Cell Lymphoma: Promising Early Results.

Myron S. Czuczman, MD, Marion Skipper, RN, Alice Mohr, NP, Zale P. Bernstein, MD, Philip McCarthy, MD, Francisco Hernandez-Ilizaliturri, MD, Asher Alban Chanan-Khan, MD

Blood (2004) 104 (11): 1396.

https://doi.org/10.1182/blood.V104.11.1396.1396

Published: 2004

Journal Articles

A Phase II Study of Velcade (V), Doxil (D) in Combination with Low-Dose Thalidomide (T) as Salvage Therapy for Patients (pts) with Relapsed (rel) or Refractory (ref) Multiple Myeloma (MM) and Waldenstorm Macroglobulinemia (WM): Encouraging Preliminary Results.

Asher Alban Chanan-Khan, MD, Kena C. Miller, NP, Philip McCarthy, MD, Laurie A. DiMiceli, Jihnee Yu, Zale P. Bernstein, MD, Myron S. Czuczman, MD

Blood (2004) 104 (11): 2421.

https://doi.org/10.1182/blood.V104.11.2421.2421

Published: 2004

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Low Incidence of Deletions of ATM (ataxia-telangiectasia mutated) Gene in Patients (pts) with Multiple Myeloma (MM) as Detected by FISH.

AMD3100 Combined with Standard Doses of G-Csf Leads to Rapid, Consistent Mobilization of Hematopoietic Progenitor Cells in Patients with Non-Hodgkin’s Lymphoma (NHL) and Multiple Myeloma.

VAD-t (Vincristine, Adriamycin, Dexamethasone and Low-Dose Thalidomide) Is an Effective Initial Therapy with High Response Rates for Patients with Treatment Naïve Multiple Myeloma (MM).

Thalidomide (T) in Combination with Fludarabine (F) as Initial Therapy for Patients (pts) with Treatment Naïve Chronic Lymphocytic Leukemia (CLL): Results of a Phase I Trial.

Phase I/II Study of Rituxan (R) in Combination with Doxil (D) in Patients (pts) with Relapsing or Refractory B-Cell Lymphoma: Promising Early Results.

A Phase II Study of Velcade (V), Doxil (D) in Combination with Low-Dose Thalidomide (T) as Salvage Therapy for Patients (pts) with Relapsed (rel) or Refractory (ref) Multiple Myeloma (MM) and Waldenstorm Macroglobulinemia (WM): Encouraging Preliminary Results.

Email alerts

ASH Publications

American Society of Hematology

Update search

Low Incidence of Deletions of ATM (ataxia-telangiectasia mutated) Gene in Patients (pts) with Multiple Myeloma (MM) as Detected by FISH.

AMD3100 Combined with Standard Doses of G-Csf Leads to Rapid, Consistent Mobilization of Hematopoietic Progenitor Cells in Patients with Non-Hodgkin’s Lymphoma (NHL) and Multiple Myeloma.

VAD-t (Vincristine, Adriamycin, Dexamethasone and Low-Dose Thalidomide) Is an Effective Initial Therapy with High Response Rates for Patients with Treatment Naïve Multiple Myeloma (MM).

Thalidomide (T) in Combination with Fludarabine (F) as Initial Therapy for Patients (pts) with Treatment Naïve Chronic Lymphocytic Leukemia (CLL): Results of a Phase I Trial.

Phase I/II Study of Rituxan (R) in Combination with Doxil (D) in Patients (pts) with Relapsing or Refractory B-Cell Lymphoma: Promising Early Results.

A Phase II Study of Velcade (V), Doxil (D) in Combination with Low-Dose Thalidomide (T) as Salvage Therapy for Patients (pts) with Relapsed (rel) or Refractory (ref) Multiple Myeloma (MM) and Waldenstorm Macroglobulinemia (WM): Encouraging Preliminary Results.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only